CureMatch will analyze molecular profiles of US Special Operations Forces cancer patients and produce reports with treatment strategies.
NEW YORK – Radiopharm Theranostics on Tuesday said it was cleared by Australian regulators to begin a Phase I trial of its KLK3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or ...
The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.
They face a difficult choice, since the treatment may benefit their children but comes with serious risks and unknowns, particularly following reports of patient deaths.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback